October 2024 in “Andrology” This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.
This study conducted a systematic review and meta-analysis but did not report results, aiming to clarify the unclear association between female pattern hair loss and polycystic ovary syndrome, along with potential links to altered fertility factors.
January 2022 in “Skin appendage disorders” The researchers concluded that while oral finasteride is effective and generally safe for treating male pattern hair loss, careful patient selection and risk assessment are important to address potential concerns such as fertility issues and mental health risks.
22 citations
,
October 2017 in “Australian & New Zealand Journal of Obstetrics & Gynaecology” This study found that the prevalence of PCOS among Australian women aged 16-29 was 12% using NIH criteria, with fertility concerns being the most distressing aspect for those diagnosed.
April 2026 in “NSUWorks (Nova Southeastern University)” This review concludes that creatine monohydrate is a safe and effective supplement, offering potential health benefits beyond athletic performance; however, it addresses concerns regarding its use among specific populations and effects on various health aspects.
